NCT06422767View on ClinicalTrials.gov

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

July 18, 2024

Primary Completion Date

April 28, 2025

Study Completion Date

April 28, 2025

Conditions

Hepatitis B

Interventions

DRUG

Bepirovirsen

Bepirovirsen will be administered.

DRUG

Placebo

Placebo will be administered.

Trial Locations (1)

78744 -1645

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

PPD Development, LP

All Listed Sponsors

collaborator

PPD Development, LP

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY